Cancer immunotherapy: the beginning of the end of cancer?
Иммунотерапия рака: начало конца рака?
2016-05-05
SCID: 54.1/wey4quz3
Discuss with AI
CTLA-4PD-1cancer immunotherapyimmune checkpoint blockadeoncolytic viruses
Figures from the paper
Abstract (AI)
These are exciting times for cancer immunotherapy. After many years of disappointing results, the tide has finally changed and immunotherapy has become a clinically validated treatment for many cancers. Immunotherapeutic strategies include cancer vaccines, oncolytic viruses, adoptive transfer of ex vivo activated T and natural killer cells, and administration of antibodies or recombinant proteins that either costimulate cells or block the so-called immune checkpoint pathways. The recent success of several immunotherapeutic regimes, such as monoclonal antibody blocking of cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD1), has boosted the development of this treatment modality, with the consequence that new therapeutic targets and schemes which combine various immunological agents are now being described at a breathtaking pace. In this review, we outline some of the main strategies in cancer immunotherapy (cancer vaccines, adoptive cellular immunotherapy, immune checkpoint blockade, and oncolytic viruses) and discuss the progress in the synergistic design of immune-targeting combination therapies.
Key Findings
1
Blocking immune checkpoints CTLA-4 and PD-1 has produced important clinical successes and accelerated development of cancer immunotherapies.
2
Cancer immunotherapy has become a clinically validated treatment for many cancers after years of disappointing results.
3
Major immunotherapeutic strategies include cancer vaccines, oncolytic viruses, adoptive transfer of activated T or natural killer cells, and immune-modulating antibodies or proteins.
4
Synergistic combinations of vaccines, cellular therapies, checkpoint blockade, and oncolytic viruses represent a major direction for advancing cancer treatment.
5
The field is rapidly identifying new therapeutic targets and designing combination regimens that integrate multiple immunological agents.
Research Object
cancer immunotherapy
Research Subject
therapeutic strategies and synergistic combination designs, including cancer vaccines, adoptive cellular immunotherapy, immune checkpoint blockade, and oncolytic viruses
Publication Details
Publication Date
2016-05-05
Journal
Publisher
ISSN
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest